Table 4. Risk factors for secondary cancer development in patients with allogeneic HSCT.

	Univariate analysis		Multivariate analysisa
Variables	HR (95% CI)	P-value	HR (95% CI)	P-value
Age ⩾40	2.79 (1.24–6.27)	0.013	2.06 (0.85–4.97)	0.109
Sex (male)	1.04 (0.48–2.24)	0.931	0.91 (0.42–1.99)	0.819
HSCT
Malignancies vs. benign	3.10 (0.93–10.32)	0.066	2.32 (0.68–7.88)	0.178
PBSCT vs BMSCT	1.83 (0.53–6.29)	0.339
Comorbidities
Diabetes mellitus	0.93 (0.13–6.86)	0.940
COPD	3.23 (1.10–9.48)	0.033	2.41 (0.78–7.40)	0.126
Chronic kidney disease	0.73 (0.10–5.41)	0.756
Liver cirrhosis	b	0.989
Autoimmune diseases	0.98 (0.13–7.28)	0.987
Dyslipidaemia	2.73 (0.81–9.27)	0.107
cGVHD	2.31 (0.97–5.51)	0.058	2.19 (0.91–5.27)	0.082
Treatment
TBI	0.95 (0.41–2.18)	0.897
Pre-HSCT radiotherapy	0.85 (0.38–1.90)	0.683
Immunosuppressantc
Cyclosporin	b	0.991
Tacrolimus	2.35 (0.70–7.89)	0.166
Methylprednisolone	1.48 (0.62–3.53)	0.373
Mycophenolate	0.71 (0.17–3.01)	0.642
Sirolimus	5.57 (0.74–41.80)	0.095	6.34 (0.81–49.29)	0.078
Anti-thymocyte globulin	0.40 (0.05–2.96)	0.367
Azathioprine	3.14 (1.44–6.88)	0.004	2.55 (1.13–5.77)	0.025
Cyclophosphamide	1.13 (0.34–3.79)	0.841
Methotrexate	1.05 (0.36–3.07)	0.926

Abbreviations: BMSCT=bone marrow stem cell transplantation; cGVHD=chronic graft vs host disease; CI=confidence interval; COPD=chronic obstructive pulmonary disease; HSCT=haematopoietic stem cell transplantation; HR=hazard ratio; PBSCT=peripheral blood stem cell transplantation; TBI: total body irradiation.

^aAll factors with P<0.1 in univariate analyses and sex were included in the Cox multivariate analysis.

^bDo not converge.

^cImmunosuppressant was analysed as a time-dependent covariate in the Cox regression model.